Genmab — April 2025
-
small new trial by The Lymphoma Academic Research Organisation - Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (E-REVRI) https://clinicaltrials.gov/study/NCT06931652
-
EPCORE
CLL-1 adds 120 patients , for Treatment-naïve (TN) and high risk (HR) CLL https://clinicaltrials.gov/study/NCT04623541?tab=history&a=26&b=27&compareMode=sideBySide#version-content-panel -
I forbindelsemed Abbvie's sag mod Genmab / Profound Bio, vil jeg høre om der er interesse for at indsamle ca. 305 USD til Proinvester så Helge og medarbed kan downloade Abbvie's indsendte beviser De ligger uploaded på PACER og kan downloades mod betaling af 0,10 USD or side. Beviserne dækker 3003 sider.
-
Er der nogen der har adgang til ØUs artikel fra 18/4. https://ugebrev.dk/formue/genmab-laserskarpt-fokus-trods-tilbageslag/
-
the Rinatabart Sesutecan Ph1/2 adds an endometrial cancer cohort, 100+ extra patients https://clinicaltrials.gov/study/NCT05579366?tab=history&a=23&b=24&compareMode=sideBySide#version-content-panel
-
Fra MW "Genmab har fået løftet kursmålet for sin amerikanske notering til 29 dollar fra 27 dollar hos den amerikanske investeringsbank Leerink Partners.
Det viser data fra Bloomberg News.
Anbefalingen er stadig "outperform".
Der går ti af Genmabs ADR-aktier på én dansk. Det nye kursmål svarer således til 1877,90 kr."
-
Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1306225/transactions-in-connection-with-share-buy-back-program
-
Amerikansk politik presser biotekaktierne https://proinvestor.com/investornyt/1306176/amerikansk-politik-presser-biotekaktierne
-
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-april-2025_en.pdf Teprotumumab
on EMA CHMP agenda -
more for the academics i guess, as it has been terminated - DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma https://elifesciences.org/reviewed-preprints/106425#x1684353369
-
ASCO25 Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy.
Abstract: 7043
| Poster Bd #: 226
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind